Fiche publication
Date publication
juin 2015
Journal
Clinical genitourinary cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Thiery-Vuillemin A, Theodore C, Jacobasch L, Schmitz J, Papandreou C, Guillot A, Emmanouilides C, Slimane K, Kelkouli N, Kim S, Nguyen Tan Hon T
Lien Pubmed
Résumé
Everolimus is a mammalian target of rapamycin (mTOR) inhibitor. It gained approval based on the results of the RECORD-1 (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism 1) trial, which included patients with metastatic renal cell carcinoma (mRCC) whose disease progressed after receiving vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). Bevacizumab is a monoclonal antibody targeting angiogenesis that is approved in patients with mRCC. The sequence of everolimus second-line therapy after failure of bevacizumab ± interferon (IFN) first-line therapy has not yet been studied.
Mots clés
Aged, Angiogenesis Inhibitors, therapeutic use, Antineoplastic Agents, administration & dosage, Bevacizumab, therapeutic use, Carcinoma, Renal Cell, drug therapy, Europe, Everolimus, administration & dosage, Female, Humans, Interferons, therapeutic use, Kidney Neoplasms, drug therapy, Male, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Survival Analysis, Treatment Outcome
Référence
Clin Genitourin Cancer. 2015 Jun;13(3):231-8
